| |
Total
|
Intestinal infection
|
Extra-intestinal infection
|
|---|
|
Antibiotic
|
Ra [n (%)]
|
I [n (%)]
|
S [n (%)]
|
R [n (%)]
|
I [n (%)]
|
S [n (%)]
|
R [n (%)]
|
I [n (%)]
|
S [n (%)]
|
|---|
|
Ampicillinc
|
108(93.9)
|
3(2.6)
|
4(3.5)
|
92(93.9)
|
2(2.0)
|
4(4.1)
|
16(94.1)
|
1(5.9)
|
0(0.0)
|
|
Amoxicillin-clavulanatec
|
15(13.0)
|
76(66.1)
|
24(20.9)
|
8(8.2)
|
68(69.4)
|
22(22.4)
|
7(41.2)
|
8(47.1)
|
2(11.8)
|
|
Imipenemb
|
3(2.6)
|
10(8.7)
|
102(88.7)
|
2(2.0)
|
7(7.1)
|
88(89.8)
|
1(5.9)
|
3(17.6)
|
14(82.4)
|
|
Ceftriaxoneb
|
17(14.8)
|
3(2.6)
|
95(82.6)
|
5(5.1)
|
3(3.1)
|
90(91.8)
|
12(70.6)
|
0(0.0)
|
5(29.4)
|
|
Cefepimeb
|
5(4.3)
|
3(2.6)
|
107(93.0)
|
1(1.0)
|
0(0.0)
|
97(99.0)
|
4(23.5)
|
3(17.6)
|
10(58.8)
|
|
Cefoxitinb
|
28(24.3)
|
6(5.2)
|
81(70.4)
|
17(17.3)
|
5(5.1)
|
76(77.6)
|
11(64.7)
|
1(5.9)
|
5(29.4)
|
|
Gentamicinb
|
6(5.2)
|
4(3.5)
|
105(91.3)
|
2(2.0)
|
2(2.0)
|
94(95.9)
|
4(23.5)
|
2(11.8)
|
11(64.7)
|
|
Nalidixic acidc
|
63(54.8)
|
–
|
52(45.2)
|
49(50.0)
|
0(0.0)
|
49(50.0)
|
14(82.4)
|
0(0.0)
|
3(17.6)
|
|
Ciprofloxacinb
|
7(6.1)
|
0(0.0)
|
108(93.9)
|
1(1.0)
|
0(0.0)
|
97(99.0)
|
6(35.3)
|
0(0.0)
|
11(64.7)
|
|
Chloramphenicolb
|
10(8.7)
|
2(1.7)
|
103(89.6)
|
8(8.2)
|
2(2.0)
|
88(89.8)
|
2(11.8)
|
0(0.0)
|
15(88.2)
|
|
Tetracyclineb
|
21(18.3)
|
5(4.3)
|
89(77.4)
|
15(15.3)
|
3(3.1)
|
80(81.6)
|
6(35.3)
|
2(11.8)
|
9(52.9)
|
|
Doxycyclinec
|
4(3.5)
|
4(3.5)
|
107(93.0)
|
2(2.0)
|
2(2.0)
|
94(95.9)
|
2(11.8)
|
2(11.8)
|
13(76.5)
|
|
Azithromycinc
|
5(4.3)
|
–
|
110(95.7)
|
0(0.0)
|
–
|
98(100.0)
|
5(29.4)
|
–
|
12(70.6)
|
|
Trimethoprim- Sulfamethoxazoleb
|
6(5.2)
|
–
|
109(94.8)
|
1(1.0)
|
0(0.0)
|
97(99.0)
|
5(29.4)
|
0(0.0)
|
12(70.6)
|
|
Sulfonamidesc
|
19 (16.5)
|
–
|
96(83.5)
|
12(12.2)
|
0(0.0)
|
86(87.8)
|
7(41.2)
|
0(0.0)
|
10(58.8)
|
- aR: Resistant; I: Intermediate; S: Sensitive
- bBreakpoints are based on the CLSI M45-A3 standards for Aeromonas spp.
- cOther breakpoints refer to the CLSI M100-S26E criteria for Enterobacteriaceae
